Affinage

IGF2BP1

Insulin-like growth factor 2 mRNA-binding protein 1 · UniProt Q9NZI8

Length
577 aa
Mass
63.5 kDa
Annotated
2026-04-28
100 papers in source corpus 47 papers cited in narrative 47 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IGF2BP1 is an oncofetal RNA-binding protein that functions as a master post-transcriptional regulator, stabilizing and controlling the translation of dozens of mRNAs—including c-MYC, ACTB, PTEN, KRAS, and IGF2—to coordinate cell proliferation, migration, neural development, and stem cell self-renewal. It binds target mRNAs through its tandem KH domains: the KH3-4 di-domain mediates sequence-specific recognition of GGAC-containing RNA via a hydrophobic surface, while the KH1-2 domains contribute an m6A-reading platform that recognizes N6-methyladenosine marks deposited by METTL3/METTL14, thereby shielding transcripts from miRNA/RISC-directed and deadenylase-mediated decay (PMID:37377445, PMID:29660014, PMID:30371874). IGF2BP1 assembles into cytoplasmic RNP granules containing 40S subunits and PABP but lacking translation initiation factors, functioning as translationally silent mRNA storage and transport particles that are critical for polarized β-actin mRNA localization in neurons and directed cell migration (PMID:17289661, PMID:36067310, PMID:22279049). Its activity is tuned by post-translational modifications—mTORC2-mediated phosphorylation at Ser181 activates IRES-dependent IGF2 translation, PRMT3-mediated methylation at Arg452 is required for mRNA-stabilizing function, FBXO45-mediated ubiquitination at Lys190/Lys450 activates it, TRIM29-mediated K48-ubiquitination at Lys440/Lys450 targets it for degradation, and ZDHHC1-mediated palmitoylation at Cys337 modulates m6A-dependent target selection—and by lncRNA cofactors such as THOR, MNX1-AS1, and HIDEN that enhance its phase separation and target engagement (PMID:23388827, PMID:37024475, PMID:34779401, PMID:38029830, PMID:39069526, PMID:30503558, PMID:36214649, PMID:37095549).

Mechanistic history

Synthesis pass · year-by-year structured walk · 19 steps
  1. 2003 High

    Addressing how IGF2BP1 achieves nucleo-cytoplasmic shuttling, two distinct nuclear export signals were mapped to KH2 and KH4, establishing that IGF2BP1 transits through the nucleus where it may first engage target mRNAs before cytoplasmic transport.

    Evidence NES mutagenesis with leptomycin B treatment and immunofluorescence in fibroblasts and spermatogenic cells

    PMID:12921532

    Open questions at the time
    • Nuclear RNA-binding events not directly demonstrated
    • Import mechanism not defined
  2. 2004 High

    The question of how IGF2BP1 achieves high-affinity RNA binding was resolved by showing it uses a cooperative sequential dimerization mechanism, where two IMP1 molecules bind target RNA in two steps to form a locked, stable RNP.

    Evidence EMSA with equilibrium and kinetic analyses on IGF2-3'UTR and H19 RNA targets

    PMID:15314207

    Open questions at the time
    • Structural basis of cooperative dimerization not resolved
    • Whether dimerization is required for all targets unknown
  3. 2006 High

    The discovery that IGF2BP1 forms a heterotrimeric RNP with PABP and UNR to repress PABP mRNA translation established its role as a translational repressor, not just a stabilizer, and defined the KH3-4 domain as its primary RNA-binding module.

    Evidence EMSA, GST pulldown, Kd measurements, and domain deletion mapping

    PMID:17212783

    Open questions at the time
    • In vivo relevance of PABP autoregulation not tested
    • Role of RRM domains in this complex unclear
  4. 2007 High

    Biochemical isolation of IGF2BP1-containing RNP granules revealed they are translationally silent storage particles containing 40S subunits and PABP but lacking eIF4E/eIF4G/60S subunits, resolving the question of how IGF2BP1 achieves mRNA silencing during transport.

    Evidence Biochemical granule purification with mass spectrometry proteomics and microarray transcriptomics

    PMID:17289661

    Open questions at the time
    • Granule assembly mechanism not defined
    • Regulation of granule disassembly and translational reactivation unknown
  5. 2012 High

    The dual mechanism by which IGF2BP1 promotes directed cell migration was established: it simultaneously represses MAPK4 translation (freeing G-actin) and stabilizes PTEN mRNA (enforcing RAC1-dependent polarization), showing that one RBP can coordinate opposing regulatory modes on different targets.

    Evidence RNAi, overexpression, co-IP, directed migration assays, and biochemical epistasis

    PMID:22279049

    Open questions at the time
    • How IGF2BP1 selectively represses versus stabilizes different targets not explained
  6. 2013 High

    Two landmark studies resolved how IGF2BP1 is regulated upstream and functions in stem cells: mTORC2 phosphorylates IGF2BP1 at Ser181 to activate IRES-dependent IGF2 translation, while genetic knockout showed IGF2BP1 operates within a Lin28a–let-7–IMP1–HMGA2 heterochronic network controlling fetal neural stem cell self-renewal.

    Evidence Kinase assays and mutagenesis in IMP1-KO MEFs; in vivo Imp1 KO with ribosome profiling and let-7/Lin28a epistasis

    PMID:23388827 PMID:24192035

    Open questions at the time
    • Other kinases that modify IGF2BP1 not surveyed
    • Whether mTORC2 phosphorylation affects m6A reading unknown
  7. 2014 High

    Functional studies in hepatocellular carcinoma established IGF2BP1 as an oncogenic mRNA stabilizer of c-MYC and MKI67, demonstrating its role in sustaining tumor growth rather than initiation.

    Evidence RIP, mRNA stability assays, IGF2BP1 knockdown in HCC cell lines and xenograft models

    PMID:24395596

    Open questions at the time
    • Mechanism of selective target stabilization in cancer not distinguished from normal cells
  8. 2015 Medium

    In vivo zebrafish studies demonstrated IGF2BP1 is required for retinal ganglion cell axon outgrowth and that β-actin 3'UTR-dependent local translation in growth cones depends on IGF2BP1 phosphorylation state, linking its transport function to axon pathfinding.

    Evidence Morpholino knockdown, RGC-specific phosphomimetic expression, and timelapse β-actin-Kaede imaging in zebrafish

    PMID:26325373

    Open questions at the time
    • Morpholino-based evidence awaits genetic mutant confirmation
    • Identity of the kinase in vivo not established
  9. 2018 High

    The central mechanism by which IGF2BP1 stabilizes mRNAs was shown to be antagonism of miRNA/RISC-mediated decay: IGF2BP1 binds 3'UTRs upstream of miRNA sites in RISC-free complexes, and its deletion increases AGO2 association with target mRNAs, establishing it as a competitive inhibitor of the miRNA pathway.

    Evidence PAR-CLIP/RIP, AGO2 IP, miRNA depletion, RISC fractionation, and in vivo metastasis models

    PMID:29660014

    Open questions at the time
    • How IGF2BP1 displaces or prevents AGO2 loading structurally is unknown
    • Whether this mechanism applies to all or a subset of targets unclear
  10. 2018 Medium

    The discovery that lncRNA THOR directly interacts with IGF2BP1 and is required for its mRNA-stabilizing function on Myc, IGF2, and Gli1 established that lncRNAs serve as essential regulatory cofactors of IGF2BP1, not just targets.

    Evidence RIP, CRISPR KO of THOR and IGF2BP1 with phenocopy, RNA pulldown, small molecule disruption

    PMID:30503558

    Open questions at the time
    • Stoichiometry and structural basis of THOR-IGF2BP1 interaction unknown
    • Whether other lncRNA cofactors are redundant not tested
  11. 2019 High

    Integration of m6A biology with IGF2BP1 function showed that it stabilizes SRF mRNA in an m6A- and miRNA-dependent manner, extending its mechanism from pure sequence-specific binding to m6A-guided target selection.

    Evidence RIP, mRNA decay assays, m6A methylation analysis, miRNA manipulation, tumor invasion assays

    PMID:30371874

    Open questions at the time
    • Relative contribution of m6A vs. GGAC sequence recognition to target selection not quantified in vivo
  12. 2020 High

    Conditional intestinal knockout revealed a non-oncogenic physiological role for IGF2BP1: it stabilizes occludin mRNA to maintain epithelial barrier integrity, and its loss causes colitis, establishing IGF2BP1 as essential for intestinal homeostasis.

    Evidence Villin-CreERT2 conditional knockout mice, RIP, mRNA stability assay, DSS-colitis model, ectopic occludin rescue

    PMID:32385106

    Open questions at the time
    • Whether other tight junction mRNAs are IGF2BP1 targets in gut not surveyed
  13. 2021 High

    The post-translational activation of IGF2BP1 was shown to involve non-degradative ubiquitination: FBXO45 ubiquitinates IGF2BP1 at Lys190 and Lys450 to activate it, upregulating PLK1 and promoting liver tumorigenesis, revealing ubiquitin as an activating signal.

    Evidence Co-IP, ubiquitination assay with site-directed mutagenesis, FBXO45 transgenic mice, PLK1 inhibition rescue

    PMID:34779401

    Open questions at the time
    • Ubiquitin chain type and mechanism of activation not determined
    • How activating vs. degradative ubiquitination is distinguished at overlapping sites (Lys450) unknown
  14. 2022 High

    IGF2BP1 knockout mice showed disorganized neocortex with reduced proliferating cells and disrupted β-actin mRNA transport in neurons, directly demonstrating its requirement for cortical development and polarized mRNA localization in vivo.

    Evidence CRISPR IGF2BP1 KO mice, BrdU labeling, endogenous β-actin-MS2 single-molecule imaging in neurons

    PMID:36067310

    Open questions at the time
    • Contribution of individual KH domains to β-actin transport in vivo not resolved
  15. 2022 High

    Chemical genetics and covalent mass spectrometry identified Cys253 in the KH1-2 domain as a druggable site: cucurbitacin B binds here and allosterically blocks m6A target recognition, establishing KH1-2 as the m6A-reading module distinct from the KH3-4 sequence-reading module.

    Evidence Covalent MS, m6A RIP, cell apoptosis assays, in vivo anti-tumor experiments

    PMID:36032766

    Open questions at the time
    • Atomic-resolution structure of KH1-2 bound to m6A RNA not available
  16. 2023 High

    NMR and biophysical studies resolved how IGF2BP1 recognizes m6A: a conserved hydrophobic platform on KH1-2 assembles on the methyl group, and this recognition is layered on top of the strong KH3-4 preference for GGAC, explaining context-dependent and concentration-dependent m6A reading.

    Evidence NMR structural analysis, fluorescence anisotropy, ITC, mutagenesis of hydrophobic platform residues

    PMID:37377445

    Open questions at the time
    • Full-length IGF2BP1 structure with bound m6A RNA not determined
    • Whether m6A reading requires prior GGAC engagement not tested kinetically
  17. 2023 High

    Multiple post-translational modifications beyond phosphorylation and ubiquitination were mapped: PRMT3 methylation at Arg452 is required for mRNA stabilization, TRIM29-mediated K48-ubiquitination at Lys440/Lys450 targets IGF2BP1 for degradation (controlling PD-L1 and immune evasion), and ZDHHC1-mediated palmitoylation at Cys337 modulates m6A-dependent activity.

    Evidence MS-based PTM mapping, site-directed mutagenesis, mRNA stability assays, immune co-culture assays, and in vivo tumor models across multiple studies

    PMID:37024475 PMID:38029830 PMID:39069526

    Open questions at the time
    • How these modifications are integrated and whether they are mutually exclusive at overlapping sites not studied
    • No structural model for how methylation or palmitoylation alters RNA binding
  18. 2023 Medium

    LncRNA and circRNA cofactors were shown to modulate IGF2BP1 phase separation and target access: MNX1-AS1 drives IGF2BP1 phase separation to enhance c-Myc/E2F1 stabilization, while circFAM13B competes at KH3-4 to reduce PKM2 mRNA binding, establishing that non-coding RNAs bidirectionally regulate IGF2BP1 activity.

    Evidence RNA pulldown, RIP, phase separation assays, KH domain mapping, mRNA stability, and xenograft models

    PMID:36214649 PMID:36747239

    Open questions at the time
    • Phase separation contribution vs. classical RNP formation not distinguished mechanistically
    • In vivo phase separation of IGF2BP1 granules not demonstrated
  19. 2024 High

    Cross-species genetic epistasis in zebrafish established that METTL16-deposited m6A marks are read by Igf2bp1 on mybl2b mRNA to control hematopoietic stem cell proliferation, and this axis is conserved in humans, validating IGF2BP1 as a bona fide m6A reader for cell cycle control.

    Evidence Zebrafish mettl16 mutants, m6A RIP, Igf2bp1 RIP, methyltransferase-dead rescue, cross-species scRNA-seq

    PMID:38605226

    Open questions at the time
    • Whether IGF2BP1 reads METTL16-deposited versus METTL3-deposited m6A marks differently is unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • A full-length atomic structure of IGF2BP1 bound to m6A-modified RNA, the rules governing whether IGF2BP1 stabilizes versus translationally represses a given target, and the integration of its multiple PTMs into a coherent regulatory code remain unresolved.
  • No full-length structure of IGF2BP1 with RNA
  • Decision logic for stabilization vs. translational repression unknown
  • PTM cross-talk (phosphorylation, ubiquitination, methylation, palmitoylation) not studied combinatorially

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 4 GO:0098772 molecular function regulator activity 3 GO:0140313 molecular sequestering activity 2
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0031410 cytoplasmic vesicle 2
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-162582 Signal Transduction 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-8953854 Metabolism of RNA 3
Partners
AGO2ELAVL1FBXO45G3BP1PABPC1SMN1TRIM29USP10
Complex memberships
IMP1 RNP granuleIMP1-PABP-UNR heterotrimeric complex

Evidence

Reading pass · 47 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 IMP1 (IGF2BP1) binds RNA by a sequential, cooperative dimerization mechanism: two IMP1 molecules bind target RNA in a two-step process, with the first step creating a low-stability intermediate and the second step converting it to a locked, stable RNP. IMP1 can also heterodimerize with other IMP family members. Electrophoretic mobility-shift assay (EMSA) with equilibrium and kinetic analyses on IGF2-3'UTR and H19 RNA targets Nucleic acids research High 15314207
2003 IMP1 contains two nuclear export signals (NESs) in KH domains 2 and 4; the KH2 NES is leucine-rich and leptomycin B-sensitive, while the KH4 NES is leptomycin B-insensitive. IMP1 can transit into the nucleus and may bind target mRNAs there to define their cytoplasmic fate. NES mutagenesis, leptomycin B treatment, immunofluorescence localization in NIH 3T3 fibroblasts and human spermatogenic cells The Biochemical journal High 12921532
2006 IMP1 interacts with poly(A)-binding protein (PABP) through its KH III–IV domain and the C-terminal PABP-C domain of PABP, independent of RNA. The KH III–IV domain of IMP1 is necessary and sufficient for binding to the adenine-rich autoregulatory sequence (ARS) of PABP mRNA, with a Kd of ~5.9 nM, forming a heterotrimeric RNP with PABP and UNR that represses PABP mRNA translation. Electrophoretic mobility-shift assay, GST pulldown, dissociation constant measurements, deletion mapping The FEBS journal High 17212783
2007 IMP1-containing RNP granules are distinct RNP entities (~100–300 nm) that contain IMPs, 40S ribosomal subunits, hnRNPs, poly(A)-binding proteins, CBP80, and exon junction complex components, but lack eIF4E, eIF4G, and 60S ribosomal subunits, indicating that embodied mRNAs are translationally silenced. Granule mRNAs are enriched for secretory pathway and ubiquitin-dependent metabolism transcripts. Biochemical isolation of IMP1-containing granules, mass spectrometry proteomics, microarray transcriptomics Molecular & cellular proteomics : MCP High 17289661
2007 IMP1 binds tau mRNA and inhibits its translation in a 3'UTR-dependent manner, and dynamically associates with polysomes during P19 neuronal differentiation in a differentiation-dependent fashion. Polysome fractionation, transfection/overexpression in HEK-293 cells, 3'UTR reporter assay Journal of neuroscience research Medium 17086542
2012 IGF2BP1 promotes tumor cell migration velocity by inhibiting translation of MAPK4 mRNA (thereby preventing MK5-mediated phosphorylation of HSP27 and releasing G-actin for F-actin polymerization) and simultaneously stabilizing PTEN mRNA (enhancing PTEN expression, shifting PIP3/PIP2 ratios, and enforcing RAC1-dependent cell polarization and directionality). RNAi knockdown, ectopic overexpression, co-immunoprecipitation, directed cell migration assays, biochemical epistasis Genes & development High 22279049
2013 mTOR complex 2 (mTORC2) phosphorylates IMP1 at Ser181 co-translationally, strongly enhancing IMP1 binding to the IGF2-leader 3 5'UTR and enabling internal ribosomal entry site (IRES)-dependent translational initiation of IGF2-leader 3 mRNA. IMP1-null fibroblasts have defective IGF2 mRNA splicing and translation, which is rescued by re-expression of phosphorylatable but not phosphorylation-defective IMP1. IMP1-knockout mouse embryonic fibroblasts, site-directed mutagenesis of Ser181, mTORC2 kinase assay, IGF2 translation rescue experiments, IRES reporter Genes & development High 23388827
2013 IGF2BP1/IMP1 physically interacts with the SMN protein and co-localizes with SMN in individual RNP granules actively transported in motor neuron axons. SMN deficiency causes reduced IMP1 axonal localization and dramatically reduced IMP1 protein levels specifically in motor neurons, not whole-brain lysates. Co-immunoprecipitation, quantitative fluorescence imaging in primary SMA motor neurons, biochemical fractionation Developmental neurobiology Medium 23897586
2013 IMP1 (IGF2BP1) post-transcriptionally inhibits expression of differentiation-associated genes while promoting self-renewal genes including Hmga2 in fetal neural stem cells. IMP1 is induced by Wnt signaling and Lin28a and is opposed by let-7 microRNAs, placing it in a heterochronic gene network (Lin28a–let-7–IMP1–HMGA2) that controls temporal changes in stem cell properties. Genetic knockout of Imp1 in mice, neural stem cell culture, ribosome profiling, epistasis with let-7 and Lin28a eLife High 24192035
2014 IGF2BP1 binds and stabilizes c-MYC and MKI67 mRNAs in hepatocellular carcinoma cells, increasing c-Myc and Ki-67 protein expression. Depletion of IGF2BP1 inhibits proliferation and induces apoptosis, and impairs tumor growth (but not initiation) in xenograft models. RNA immunoprecipitation (RIP), mRNA stability assays, IGF2BP1 knockdown in multiple HCC cell lines, xenograft mouse models Hepatology (Baltimore, Md.) High 24395596
2014 IGF2BP1 drives translation of cIAP1 mRNA in rhabdomyosarcoma cells, promoting cIAP1 protein expression and conferring resistance to TNF-α-mediated apoptosis. IGF2BP1 knockdown reduces cIAP1 and sensitizes cells to death. IGF2BP1 knockdown, cIAP1 translational reporter assay, apoptosis/cell death assays, xenograft survival studies Oncogene Medium 24704827
2015 IGF2BP1 binds and stabilizes ETV6/RUNX1 fusion mRNA in t(12;21)-positive ALL cells, as shown by immunoprecipitation of endogenous IGF2BP1 followed by two-fold IGF2BP1 downregulation causing a corresponding decrease in ETV6/RUNX1 mRNA. RNA immunoprecipitation (RIP) of endogenous IGF2BP1, siRNA-mediated knockdown, qRT-PCR in cell line and primary ALL samples Blood cells, molecules & diseases Medium 26852652
2016 IMP1 interacts with the KH3-4 domain with target mRNAs (PTGS2, GDF15, IGF-2) and suppresses breast tumor growth and metastasis. Deletion of the KH3-4 domain of IMP1 abrogates these tumor-suppressive effects. KH34 domain deletion mutants, RNA pulldown, microarray, mouse xenograft model Oncotarget Medium 26910917
2017 IGF2BP1 overexpression in human adult erythroblasts induces fetal-like hemoglobin expression by reducing BCL11A protein expression through post-transcriptional mechanisms (mRNA stability and translational regulation of BCL11A), leading to increased gamma-globin and decreased beta-globin transcripts. Erythroid-specific lentiviral overexpression, mRNA stability assays, polysome profiling, flow cytometry for hemoglobin quantification Proceedings of the National Academy of Sciences of the United States of America High 28652347
2018 IGF2BP1 preferentially associates with mRNA 3'UTRs upstream of miRNA binding sites and impairs miRNA-directed decay of target mRNAs by associating with them in RISC-free complexes. IGF2BP1 deletion enhances association of target mRNAs with AGO2, and its activity is abrogated at low miRNA abundance. PAR-CLIP/RIP, AGO2 immunoprecipitation, miRNA depletion experiments, RISC fractionation, in vivo xenograft metastasis model Nucleic acids research High 29660014
2019 IGF2BP1 promotes SRF mRNA stability in an m6A- and miRNA-dependent manner, preventing miRNA-directed decay of SRF mRNA. This results in increased SRF transcriptional activity, which IGF2BP1 also sustains post-transcriptionally by stabilizing SRF target gene mRNAs including PDLIM7 and FOXK1. RIP, mRNA decay assays, m6A methylation analysis, miRNA manipulation, transcriptomics, tumor cell growth and invasion assays Nucleic acids research High 30371874
2018 LncRNA THOR directly interacts with IGF2BP1 protein and is required for IGF2BP1 to stabilize its mRNA targets (Myc, IGF2, Gli1). CRISPR knockout of THOR or IGF2BP1 phenocopies each other, and small molecule triptonide disrupts the THOR-IGF2BP1 association causing target mRNA depletion. RIP, CRISPR/Cas9 knockout, ectopic overexpression, RNA pulldown, small molecule treatment, xenograft Cancer letters Medium 30503558
2019 IGF2BP1 regulates the cargo of extracellular vesicles (EVs) secreted by melanoma cells, affecting pro-metastatic EV function. IGF2BP1 knockdown alters the mRNA, protein, and miRNA content of EVs and blocks pre-metastatic niche formation, without affecting EV size, number, or uptake. Genetic IGF2BP1 deletion/knockdown, in vivo lung metastasis models, RNA-sequencing and proteomics of EVs, EV uptake assays Oncogene Medium 30936459
2019 IGF2BP1 co-immunoprecipitates with the p65-p52 NFκB complex in nuclei of LPS-treated macrophages, and IGF2BP1 knockdown or CRISPR knockout inhibits p65-p52 nuclear translocation and NFκB activation, thereby reducing pro-inflammatory cytokine (TNF-α, IL-1β, IL-6) production. Co-immunoprecipitation, CRISPR/Cas9 knockout, shRNA knockdown, ELISA, NFκB reporter assay in THP-1 macrophages and PBMCs Biochemical and biophysical research communications Medium 31000200
2020 The oncopeptide RBRP (encoded by LINC00266-1) binds IGF2BP1 and strengthens its m6A recognition on target RNAs such as c-Myc mRNA, increasing mRNA stability and c-Myc expression. RBRP serves as a regulatory subunit of the IGF2BP1 m6A reader complex. Co-immunoprecipitation, RNA pulldown, m6A RIP, mRNA stability assays, functional cancer cell assays Nature communications High 32245947
2020 IMP1 binds and stabilizes occludin (OCLN) mRNA via direct interaction, promoting occludin protein expression in intestinal epithelial cells to maintain barrier function. IGF2BP1 intestinal-epithelial-specific knockout causes colitis and increased permeability, and ectopic occludin expression in IGF2BP1-knockdown cells restores barrier function. Conditional (Villin-CreERT2) Igf2bp1 knockout mice, RIP, mRNA stability assay, gut permeability assay, DSS-colitis model, ectopic rescue The Journal of biological chemistry High 32385106
2021 IGF2BP1 recognizes m6A sites in the 3'UTR of PEG10 mRNA and recruits PABPC1 to enhance PEG10 mRNA stability, increasing PEG10 protein expression that represses p16 and p18 to accelerate the cell cycle in endometrial cancer. MeRIP-seq, RIP-seq, co-immunoprecipitation + mass spectrometry, mRNA stability assay, RNA pulldown, xenograft Theranostics High 33391523
2021 FBXO45 E3 ubiquitin ligase promotes IGF2BP1 ubiquitination at Lys190 and Lys450, leading to IGF2BP1 activation (not degradation), which upregulates PLK1 expression and promotes liver tumorigenesis. Co-immunoprecipitation, ubiquitination assay with site-directed mutagenesis, IGF2BP1 knockdown, FBXO45 transgenic mice, PLK1 inhibition rescue eLife High 34779401
2021 A small molecule targeting the hydrophobic surface at the KH3-KH4 domain boundary of IGF2BP1 inhibits its binding to KRAS RNA, reducing Kras and other IGF2BP1 mRNA targets, lowering Kras protein, and inhibiting downstream signaling and cell migration. Fluorescence anisotropy binding assays, surface plasmon resonance, domain mapping, RT-qPCR, wound healing assay, soft agar growth RNA biology High 34895045
2022 Cucurbitacin B (CuB) directly targets IGF2BP1 at Cys253 in the KH1-2 domains, inducing an allosteric effect that blocks IGF2BP1 recognition of m6A mRNA targets such as c-MYC, demonstrating that the KH1-2 domains are functionally important for m6A target recognition. Chemical genetics, covalent mass spectrometry, m6A RIP, cell apoptosis assays, in vivo anti-tumor experiments ACS central science High 36032766
2022 LncRNA MNX1-AS1 binds IGF2BP1 and drives its phase separation, which increases IGF2BP1 interaction with the 3'UTR of c-Myc and E2F1 mRNA, enhancing their stability and accelerating cell-cycle progression in NSCLC. RNA pulldown, RIP, phase separation assays, mRNA stability assay, in vitro and in vivo tumor models, PDX model Cancer research Medium 36214649
2022 IGF2BP1 stabilizes SMAD1 mRNA through m6A modification-dependent recognition, and METTL14-mediated m6A methylation is required for IGF2BP1 to recognize and stabilize SMAD1 mRNA to promote osteogenic differentiation. Me-RIP, RIP, luciferase reporter assay, METTL14 and IGF2BP1 knockdown, osteogenic differentiation assays, OVX mouse model Cell death & disease Medium 36319624
2022 IGF2BP1 stabilizes MIR210HG lncRNA transcript through m6A modification in cooperation with ELAVL1 as a co-factor, and IGF2BP1 is directly transcriptionally activated by MYCN via E-box binding. RIP, m6A MeRIP, RNA stability assay, ChIP for MYCN/E-box, co-immunoprecipitation with ELAVL1 Cell & bioscience Medium 35346372
2022 IGF2BP1 directly binds the 3'UTR of JAK2 mRNA via m6A sites, enhancing JAK2 mRNA stability and activating JAK2/STAT3 signaling in endothelial cells. METTL3-mediated m6A methylation promotes the METTL3-IGF2BP1-JAK2 axis. MeRIP, RIP, RNA pulldown, luciferase reporter, actinomycin D mRNA stability, METTL3 knockdown rescue Frontiers in cell and developmental biology Medium 34950654
2023 PRMT3 methylates IGF2BP1 at Arg452, and this methylation is critical for IGF2BP1 function in stabilizing HEG1 mRNA, thereby promoting oxaliplatin resistance in hepatocellular carcinoma. CRISPR/Cas9 activation screen, mass spectrometry identification of methylation site, site-directed mutagenesis of R452, mRNA stability assay, in vitro and in vivo functional validation Nature communications High 37024475
2023 USP10 deubiquitinase directly binds and deubiquitinates IGF2BP1, stabilizing it at higher protein levels. The stabilized IGF2BP1 then recognizes m6A sites on CPT1A mRNA, enhancing CPT1A mRNA stability to promote breast cancer metastasis. Co-immunoprecipitation, ubiquitination assay, MeRIP-seq, mRNA stability assay, in vitro and in vivo metastasis assays International journal of biological sciences Medium 36632454
2023 TRIM29 E3 ubiquitin ligase interacts with IGF2BP1 and induces its K48-linked ubiquitination at Lys440 and Lys450, leading to IGF2BP1 protein degradation. Loss of TRIM29-mediated degradation allows IGF2BP1 to stabilize PD-L1 mRNA via m6A-dependent binding to its 3'UTR, promoting immune evasion. Co-immunoprecipitation, ubiquitination site mapping by mutagenesis, MeRIP, mRNA stability assay, T-cell co-culture immune assays, in vivo tumor models Cancer letters High 38029830
2023 RPS15 interacts with the K homology domain of IGF2BP1; together they bind the 3'UTR of MKK6 and MAPK14 mRNAs in an m6A-dependent manner, promoting translation of core p38 MAPK pathway proteins to drive ESCC metastasis. Co-immunoprecipitation, RIP-seq, m6A-dependent binding assays, p38 MAPK pathway analysis, in vivo metastasis assays Signal transduction and targeted therapy Medium 37264021
2023 IGF2BP1 stabilizes E2F1 mRNA in an m6A-dependent manner (validated by actinomycin D chase and EMSA); the increased E2F1 acts as a transcription factor to promote MIF expression, driving NLRP3-mediated pyroptosis in renal tubular cells. EMSA, actinomycin D mRNA stability assay, MeRIP mutation/luciferase, ChIP, in vivo CLP mouse model International journal of biological sciences Medium 36632449
2023 IGF2BP1 directly binds and stabilizes SEMA3A and SHMT2 mRNAs in neuroblastoma cells, and modulates their protein levels in secreted extracellular vesicles to form a pro-metastatic microenvironment. RIP, proteomic analysis of EVs from IGF2BP1 knockdown/overexpression, immunocompetent mouse metastasis models Oncogene Medium 36973517
2023 MKRN3 physically interacts with IGF2BP1 (identified by proteomics), and Mkrn3 deletion in hypothalamic neurons increases dendritic spine density and alters hypothalamic plasticity, with IGF2BP1 interacting with polyadenylate-binding protein family members in the MKRN3 interactome. Proteomics/interactome analysis, co-immunoprecipitation, Mkrn3 conditional mouse knockout, dendritic spine imaging JCI insight Medium 37092553
2023 The m6A recognition mechanism of IMP1 involves a dedicated hydrophobic platform on the protein that assembles on the methyl moiety of m6A, creating a stable high-affinity interaction. This recognition is conserved, independent of flanking sequence context, but layered on top of IMP1's strong sequence preference for GGAC RNA, suggesting a context-dependent role for m6A in IMP1 target selection dependent on cellular IMP1 concentration. NMR, in vitro binding assays (fluorescence anisotropy, ITC), mutagenesis of the hydrophobic platform, evolutionary conservation analysis Nucleic acids research High 37377445
2023 STAT3 binds the IGF2BP1 promoter to transcriptionally activate IGF2BP1 expression; IGF2BP1 in turn binds RELA mRNA and stabilizes it, promoting NFκB/RELA-mediated inflammatory responses in endometriosis. ChIP assay (STAT3 binding to IGF2BP1 promoter), dual-luciferase reporter, RIP and RNA pulldown (IGF2BP1-RELA mRNA) Pharmaceutical biology Medium 37095705
2023 The desert lncRNA HIDEN facilitates the interaction between IMP1 and FZD5 mRNA; HIDEN depletion reduces IMP1-FZD5 mRNA interaction and causes FZD5 mRNA destabilization, reducing WNT activity and impairing definitive endoderm differentiation from human pluripotent stem cells. RIP demonstrating reduced IMP1-FZD5 mRNA interaction upon HIDEN knockdown, mRNA stability assay, WNT reporter, human iPSC differentiation system Genome biology Medium 37095549
2023 ZDHHC1 palmitoylates IGF2BP1 at Cys337 (S-palmitoylation), which causes downregulation of LIPG mRNA stability in an m6A-dependent manner, suppressing colorectal cancer cell growth. Palmitoylation assay, site-directed mutagenesis of C337, m6A MeRIP, mRNA stability assay, in vivo xenograft Cancer gene therapy Medium 39069526
2022 IGF2BP1 knockout mice exhibit disorganized neocortex development, reduced cortical marginal cell density, fewer mitotically active cells, and in IGF2BP1-knockout neurons, β-actin mRNA shows increased transcription rates and total protein content but decreased transport and anchoring. IGF2BP1 knockout mouse (CRISPR), BrdU labeling, β-actin-MS2 endogenous tagging for single-molecule mRNA imaging, FRAP-related transport assays in neurons Proceedings of the National Academy of Sciences of the United States of America High 36067310
2015 Igf2bp1 is required for RGC axon outgrowth in vivo in zebrafish; a phosphomimetic Igf2bp1 reduces axonal projection density in the optic tract without killing RGCs. The β-actin 3'UTR is sufficient to drive local translation in pathfinding growth cones in vivo. Igf2bp1 morpholino knockdown in zebrafish, RGC-specific phosphomimetic expression, timelapse imaging of β-actin-Kaede reporter in growth cones PloS one Medium 26325373
2024 Mettl16-mediated m6A modification stabilizes mybl2b mRNA via the m6A reader Igf2bp1; Mettl16 deficiency destabilizes mybl2b mRNA due to lost Igf2bp1 binding, causing G1/S cell cycle arrest in embryonic hematopoietic stem and progenitor cells. The METTL16-m6A-MYBL2-IGF2BP1 axis is conserved in humans. Zebrafish mettl16 mutants, m6A RIP/MeRIP, Igf2bp1 RIP, cell cycle analysis, cross-species single-cell RNA-seq, methyltransferase-dead Mettl16 rescue The EMBO journal High 38605226
2023 circFAM13B competitively binds to the KH3-4 domains of IGF2BP1, reducing IGF2BP1 binding to PKM2 mRNA 3'UTR and decreasing PKM2 mRNA stability, thereby inhibiting glycolysis in bladder cancer cells. RNA pulldown, mass spectrometry, RIP, KH domain binding mapping, mRNA stability assay, co-culture immune assays Journal of experimental & clinical cancer research : CR Medium 36747239
2023 IGF2BP1 binds and stabilizes INHBA mRNA; IGF2BP1 also interacts with G3BP1 (stress granule assembly factor), and the IGF2BP1-INHBA-Smad2/3 signaling axis promotes ESCC cell invasion and migration. RIP-seq, mass spectrometry identifying G3BP1 interaction, RNA pulldown, mRNA stability assay, gene-specific m6A PCR, immunofluorescence Experimental hematology & oncology Medium 37644505
2018 IMP1 binds UCA1 lncRNA via 'ACACCC' motifs and destabilizes UCA1 through recruitment of the CCR4-NOT1 deadenylase complex; this IMP1-UCA1 interaction also competes for miR-122-5p binding to UCA1, freeing miR-122-5p to act on its target mRNAs and thereby reducing cell invasion. RIP, RNA pulldown, CCR4-NOT1 co-immunoprecipitation, transwell invasion, loss- and gain-of-function experiments Breast cancer research : BCR Medium 29669595
2025 IGF2BP1 stabilizes AIFM2 mRNA via m6A modification to regulate ferroptosis suppression and glycolysis promotion in hepatocellular carcinoma; IGF2BP1 knockdown reduces glycolysis, suppresses AIFM2, and promotes ferroptosis, all reversed by AIFM2 overexpression. MeRIP assay, actinomycin D mRNA stability assay, IGF2BP1/AIFM2 knockdown/overexpression, ferroptosis marker assays, xenograft and lung metastasis models Cellular signalling Medium 39971223

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2019 IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner. Nucleic acids research 303 30371874
2018 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. Journal of hematology & oncology 228 29954406
2020 An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis. Nature communications 222 32245947
2007 Molecular composition of IMP1 ribonucleoprotein granules. Molecular & cellular proteomics : MCP 187 17289661
2021 IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression. Theranostics 172 33391523
2014 Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma. Hepatology (Baltimore, Md.) 159 24395596
2022 Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment. ACS central science 129 36032766
2012 IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Genes & development 127 22279049
2018 IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic acids research 115 29660014
2004 Sequential dimerization of human zipcode-binding protein IMP1 on RNA: a cooperative mechanism providing RNP stability. Nucleic acids research 111 15314207
2013 A network of heterochronic genes including Imp1 regulates temporal changes in stem cell properties. eLife 96 24192035
2021 N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1. Frontiers in cell and developmental biology 88 34950654
2023 HNRNPL induced circFAM13B increased bladder cancer immunotherapy sensitivity via inhibiting glycolysis through IGF2BP1/PKM2 pathway. Journal of experimental & clinical cancer research : CR 79 36747239
2018 Triptonide inhibits human nasopharyngeal carcinoma cell growth via disrupting Lnc-RNA THOR-IGF2BP1 signaling. Cancer letters 79 30503558
2023 PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nature communications 76 37024475
2013 mTOR complex 2 phosphorylates IMP1 cotranslationally to promote IGF2 production and the proliferation of mouse embryonic fibroblasts. Genes & development 76 23388827
2013 Dynamics of survival of motor neuron (SMN) protein interaction with the mRNA-binding protein IMP1 facilitates its trafficking into motor neuron axons. Developmental neurobiology 75 23897586
2022 MNX1-AS1 Promotes Phase Separation of IGF2BP1 to Drive c-Myc-Mediated Cell-Cycle Progression and Proliferation in Lung Cancer. Cancer research 72 36214649
2022 Downregulation of METTL14 improves postmenopausal osteoporosis via IGF2BP1 dependent posttranscriptional silencing of SMAD1. Cell death & disease 69 36319624
2018 A cancer-testis non-coding RNA LIN28B-AS1 activates driver gene LIN28B by interacting with IGF2BP1 in lung adenocarcinoma. Oncogene 67 30353165
2023 Stabilization of IGF2BP1 by USP10 promotes breast cancer metastasis via CPT1A in an m6A-dependent manner. International journal of biological sciences 66 36632454
2021 Small molecule inhibitor of Igf2bp1 represses Kras and a pro-oncogenic phenotype in cancer cells. RNA biology 61 34895045
2015 miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma. Cell proliferation 60 26332146
2021 Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation. eLife 59 34779401
2000 Som1, a third component of the yeast mitochondrial inner membrane peptidase complex that contains Imp1 and Imp2. Molecular & general genetics : MGG 58 10821182
2019 Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis. Oncogene 56 30936459
2015 miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1. Molecular cancer 55 25889892
2002 IMP-1 metallo-beta-lactamase: effect of chelators and assessment of metal requirement by electrospray mass spectrometry. Biochimica et biophysica acta 55 12090933
2023 TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer. Cancer letters 54 38029830
2012 IGF2BP1: a post-transcriptional "driver" of tumor cell migration. Cell adhesion & migration 49 22983196
2003 Nuclear transit of human zipcode-binding protein IMP1. The Biochemical journal 48 12921532
2018 IMP1 regulates UCA1-mediated cell invasion through facilitating UCA1 decay and decreasing the sponge effect of UCA1 for miR-122-5p. Breast cancer research : BCR 47 29669595
2014 IGF2BP1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylases. Stem cells and development 47 24915579
2021 IGF2BP1 Promotes the Liver Cancer Stem Cell Phenotype by Regulating MGAT5 mRNA Stability by m6A RNA Methylation. Stem cells and development 46 34514861
2020 The mRNA-binding protein IGF2BP1 maintains intestinal barrier function by up-regulating occludin expression. The Journal of biological chemistry 46 32385106
2022 MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification. Cell & bioscience 45 35346372
2018 TOR-autophagy branch signaling via Imp1 dictates plant-microbe biotrophic interface longevity. PLoS genetics 45 30462633
2014 IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1. Oncogene 45 24704827
2017 IGF2BP1 overexpression causes fetal-like hemoglobin expression patterns in cultured human adult erythroblasts. Proceedings of the National Academy of Sciences of the United States of America 43 28652347
2015 Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon. Molecular cancer research : MCR 43 26194191
2023 Inhibition of IGF2BP1 attenuates renal injury and inflammation by alleviating m6A modifications and E2F1/MIF pathway. International journal of biological sciences 41 36632449
2023 RPS15 interacted with IGF2BP1 to promote esophageal squamous cell carcinoma development via recognizing m6A modification. Signal transduction and targeted therapy 40 37264021
2020 LIN28B-AS1-IGF2BP1 binding promotes hepatocellular carcinoma cell progression. Cell death & disease 37 32917856
2021 IGF2BP1, a Conserved Regulator of RNA Turnover in Cancer. Frontiers in molecular biosciences 35 33829040
2017 MicroRNA-124-3p inhibits cell growth and metastasis in cervical cancer by targeting IGF2BP1. Experimental and therapeutic medicine 35 29399123
2016 Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. Growth factors (Chur, Switzerland) 35 27126374
2011 Structural and kinetic studies on metallo-β-lactamase IMP-1. Biochemistry 35 21928807
2007 Dynamic association with polysomes during P19 neuronal differentiation and an untranslated-region-dependent translation regulation of the tau mRNA by the tau mRNA-associated proteins IMP1, HuD, and G3BP1. Journal of neuroscience research 34 17086542
2006 IMP1 interacts with poly(A)-binding protein (PABP) and the autoregulatory translational control element of PABP-mRNA through the KH III-IV domain. The FEBS journal 34 17212783
1981 IMP1/imp1: a gene involved in the nucleo-mitochondrial control of galactose fermentation in Saccharomyces cerevisiae. Genetics 34 7021320
2020 miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma. Molecular carcinogenesis 33 33052627
2016 IMP1 suppresses breast tumor growth and metastasis through the regulation of its target mRNAs. Oncotarget 33 26910917
2023 RUNX1-IT1 favors breast cancer carcinogenesis through regulation of IGF2BP1/GPX4 axis. Discover oncology 32 37036576
2022 m6A Reader Igf2bp1 Regulates the Inflammatory Responses of Microglia by Stabilizing Gbp11 and Cp mRNAs. Frontiers in immunology 28 35572575
2020 microRNA-670 modulates Igf2bp1 expression to regulate RNA methylation in parthenogenetic mouse embryonic development. Scientific reports 28 32179813
2008 [Dissemination of IMP-1 and OXA type beta-lactamase in carbapenem-resistant Acinetobacter baumannii]. The Korean journal of laboratory medicine 28 18309251
2023 Elevated expression of the RNA-binding protein IGF2BP1 enhances the mRNA stability of INHBA to promote the invasion and migration of esophageal squamous cancer cells. Experimental hematology & oncology 27 37644505
2015 ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. Blood cells, molecules & diseases 26 26852652
2022 SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis. Journal of gynecologic oncology 25 36245227
2017 Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. PloS one 25 28486549
2022 LncRNA metastasis-associated lung adenocarcinoma transcript-1 promotes osteogenic differentiation of bone marrow stem cells and inhibits osteoclastic differentiation of Mø in osteoporosis via the miR-124-3p/IGF2BP1/Wnt/β-catenin axis. Journal of tissue engineering and regenerative medicine 24 34962086
2022 N6-methyladenosine (m6A) reader IGF2BP1 accelerates gastric cancer aerobic glycolysis in c-Myc-dependent manner. Experimental cell research 24 35489385
2020 LINC01426 contributes to clear cell renal cell carcinoma progression by modulating CTBP1/miR-423-5p/FOXM1 axis via interacting with IGF2BP1. Journal of cellular physiology 24 32583425
2019 IGF2BP1 promotes LPS-induced NFκB activation and pro-inflammatory cytokines production in human macrophages and monocytes. Biochemical and biophysical research communications 24 31000200
2019 LncRNA THOR promotes tongue squamous cell carcinomas by stabilizing IGF2BP1 downstream targets. Biochimie 24 31220513
2023 IGF2BP1 regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis. Oncogene 23 36973517
2023 MKRN3 inhibits puberty onset via interaction with IGF2BP1 and regulation of hypothalamic plasticity. JCI insight 22 37092553
2025 CircRNF13 enhances IGF2BP1 phase separation-mediated ITGB1 mRNA stabilization in an m6A-dependent manner to promote oral cancer cisplatin chemoresistance. Molecular cancer 20 39891203
2023 METTL3 potentiates osteogenic differentiation of bone marrow mesenchymal stem cells via IGF2BP1/m6A/RUNX2. Oral diseases 20 36705430
2014 IMP-1 encoded by a novel Tn402-like class 1 integron in clinical Achromobacter xylosoxidans, China. Scientific reports 20 25428613
2013 High-throughput fluorescence anisotropy screen for inhibitors of the oncogenic mRNA binding protein, IMP-1. Journal of biomolecular screening 20 24108120
2024 A Mettl16/m6A/mybl2b/Igf2bp1 axis ensures cell cycle progression of embryonic hematopoietic stem and progenitor cells. The EMBO journal 19 38605226
2023 Direct m6A recognition by IMP1 underlays an alternative model of target selection for non-canonical methyl-readers. Nucleic acids research 19 37377445
2023 Development of a specific and potent IGF2BP1 inhibitor: A promising therapeutic agent for IGF2BP1-expressing cancers. European journal of medicinal chemistry 19 37976707
2018 The LIN28B-IMP1 post-transcriptional regulon has opposing effects on oncogenic signaling in the intestine. Genes & development 19 30068703
2017 Dicer loss and recovery induce an oncogenic switch driven by transcriptional activation of the oncofetal Imp1-3 family. Genes & development 19 28446596
2024 ZDHHC1 downregulates LIPG and inhibits colorectal cancer growth via IGF2BP1 Palmitoylation. Cancer gene therapy 18 39069526
2023 Feedforward loop between IMP1 and YAP/TAZ promotes tumorigenesis and malignant progression in glioblastoma. Cancer science 18 36308276
2022 Tagged actin mRNA dysregulation in IGF2BP1[Formula: see text] mice. Proceedings of the National Academy of Sciences of the United States of America 18 36067310
2021 circBICD2 targets miR-149-5p/IGF2BP1 axis to regulate oral squamous cell carcinoma progression. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 18 33382158
2019 microRNA-4500 inhibits human glioma cell progression by targeting IGF2BP1. Biochemical and biophysical research communications 18 31000197
2016 Defining the significance of IGF2BP1 overexpression in t(12;21)(p13;q22)-positive leukemia REH cells. Leukemia research 18 27239736
2024 LRRC75A-AS1 Drives the Epithelial-Mesenchymal Transition in Cervical Cancer by Binding IGF2BP1 and Inhibiting SYVN1-Mediated NLRP3 Ubiquitination. Molecular cancer research : MCR 17 38180377
2023 A desert lncRNA HIDEN regulates human endoderm differentiation via interacting with IMP1 and stabilizing FZD5 mRNA. Genome biology 17 37095549
2022 Computational modelling of potential Zn-sensitive non-β-lactam inhibitors of imipenemase-1 (IMP-1). Journal of biomolecular structure & dynamics 17 36476097
2020 LncRNA PCAT6 Regulated by YY1 Accelerates the Progression of Glioblastoma via miR-513/IGF2BP1. Neurochemical research 17 32990800
2020 Eimeria tenella: IMP1 protein delivered by Lactococcus lactis induces immune responses against homologous challenge in chickens. Veterinary parasitology 17 33248421
1992 Allelism of IMP1 and GAL2 genes of Saccharomyces cerevisiae. Journal of bacteriology 17 1577709
2023 Silencing of circCRIM1 Drives IGF2BP1-Mediated NSCLC Immune Evasion. Cells 16 36672208
2023 N6-methyladenosine (m6A) reader IGF2BP1 facilitates clear-cell renal cell carcinoma aerobic glycolysis. PeerJ 16 36691477
2015 Characterization of the Eimeria maxima sporozoite surface protein IMP1. Veterinary parasitology 16 26012860
2015 The RNA Binding Protein Igf2bp1 Is Required for Zebrafish RGC Axon Outgrowth In Vivo. PloS one 16 26325373
2023 Ligustrazine inhibits inflammatory response of human endometrial stromal cells through the STAT3/IGF2BP1/RELA axis. Pharmaceutical biology 15 37095705
2021 Inhibition of the mRNA-Binding Protein IGF2BP1 Suppresses Proliferation and Sensitizes Neuroblastoma Cells to Chemotherapeutic Agents. Frontiers in oncology 15 33796454
2019 Molecular and epidemiological analysis of IMP-1 metallo-β-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 15 30611637
2025 IGF2BP1/AIFM2 axis regulates ferroptosis and glycolysis to drive hepatocellular carcinoma progression. Cellular signalling 14 39971223
2023 Tumor suppressive function of IGF2BP1 in gastric cancer through decreasing MYC. Cancer science 14 38115228
2022 m6A-binding protein IGF2BP1 promotes the malignant phenotypes of lung adenocarcinoma. Frontiers in oncology 14 36249006
2021 The InDel variants of sheep IGF2BP1 gene are associated with growth traits. Animal biotechnology 14 34255980
1991 The yeast IMP1 gene is allelic to GAL2. Molecular & general genetics : MGG 14 1745225